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Abstract 
Purpose: Although the majority of recurrences occur within the first 3 years of 
hysterectomy for endometrioid carcinoma, we report herein a successful salvage vaginal 
brachytherapy in a patient with endometrioid uterine carcinoma which recurred more 
than 17 years after initial treatment.  
Materials and Methods: A 61-year-old female was diagnosed with endometrioid 
adenocarcinoma of the uterus and treated with TAH-BSO, followed by adjuvant external 
beam radiation therapy (EBRT) to the whole pelvis. After remaining free of any recurrent 
or metastatic disease for more than 17 years, she was diagnosed with isolated vaginal 
cuff recurrence and successfully treated with a salvage high-dose-rate intracavitary 
vaginal brachytherapy.  
Results: The patient remained disease free until her death from unrelated causes 7 years 
later.  
Conclusion: To the best of our knowledge, this case represents the longest time to 
recurrence of endometrial cancer in someone who had been treated with TAH-BSO and 
adjuvant pelvic EBRT. This case highlights that even with adjuvant therapy, late 
recurrences may occur, and successful salvage brachytherapy is very effective.  
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Introduction 
Endometrial carcinoma is the most common gynecologic malignancy, with 43,470 new 
cases estimated to have been diagnosed in 2010 [1]. Patients undergoing surgical staging 
with or without adjuvant radiation therapy have reported disease recurrence rates 
between 3 and 15% for FIGO stages I–II [2, 3]. Of those malignancies that do recur, 76–
87% are evident within the first 3 years of treatment initiation [2, 4]. Here, we report a 
case of endometrioid uterine adenocarcinoma which recurred 210 months (17.5 years) 
after treatment. Based on a review of the literature, our patient represents the longest time 
to recurrence after hysterectomy and adjuvant external beam radiation therapy (EBRT). 
The case and its treatment are discussed, followed by a review of the relevant literature. 
Case Report 
In December 1984, a 61-year-old Caucasian female presented after a routine screening Papanicolaou 
(Pap) smear revealed cells suspicious for adenocarcinoma. An endometrial biopsy via dilation and 
curettage showed endometrioid adenocarcinoma of the uterus, FIGO grade II. The patient subsequently 
underwent surgical staging with TAH-BSO selective lymph node dissection and peritoneal washing on 
January 15, 1985. A final pathology revealed 1988 FIGO stage IC endometrioid adenocarcinoma, FIGO 
grade I, with invasion of 16 mm out of the 21-mm thickness of the myometrium. All 16 lymph nodes 
examined were negative for metastatic disease. Peritoneal washing was negative for malignant cells. The 
patient was then treated with adjuvant EBRT to the whole pelvis to a total dose of 45 Gray in 25 
fractions of 1.8 Gray each, using a 4-field pelvic box technique. Radiation therapy was completed on 
March 1, 1985. 
The patient remained under close follow-up and was without any evidence of recurrent disease until 
July 2001. At that time, a routine follow-up Pap smear revealed adenocarcinoma. Pelvic examination 
revealed superficial induration at the vaginal vault. Vaginal cuff biopsy was preformed in January 2002, 
which confirmed recurrent endometrioid carcinoma, FIGO grade 1 with ER/PR-positive stain (fig. 1). 
Re-staging CT scan of the abdomen and pelvis in January 2002 was negative for any local or metastatic 
disease. Interim medical history remained non-contributory. 
Our patient was treated with a salvage high-dose-rate (HDR) intracavitary vaginal cuff 
brachytherapy to the upper 4 cm of the vaginal length to a dose of 30 Gray in 5 fractions of 6 Gray each, 
1–2 fractions per week, prescribed to 0.5 cm depth, which was completed in September 2002. Treatment 
was well tolerated with no grade II adverse effects. Subsequently, she underwent routine follow-up with 
gynecologic and radiation oncology services via clinical examination, routine Pap smear, and routine 
imaging studies with CT scans of the abdomen and pelvis. For more than 7 years after the salvage 
treatment, our patient remained free of recurrent or persistent disease. She died in September 2009 from 
unrelated causes at the age of 88.  
Discussion 
After treatment with TAH-BSO, the most common site of endometrioid carcinoma 
recurrence is the vaginal cuff. Approximately 75% of recurrences occur at this site without 
adjuvant therapy. Although adjuvant radiotherapy reduces locoregional recurrence, the 
vaginal cuff still remains the most common site of relapse within the pelvis [2, 5]. 
The majority of recurrences occur within the first 3 years of treatment. Most initial 
relapses had occurred within 18 months in the GOG 99 trial [3]. The PORTEC Study 
Group reported a median time to recurrence of 21 months (range 3–108 months) [2]. A 
meta-analysis of 12 trials including 2,922 patients, found that 70–100% of recurrences 
occurred within 3 years of treatment, with a range of recurrences between 2 and 194  
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months. It was also described that those at low risk of recurrence (age <60, stage IA, IB 
disease in 1988 FIGO) had only a 1–3% risk of recurrence, compared to the 13% 
recurrence rate seen amongst the entire cohort primarily composed of stage I–II patients 
[6].  
Our patient’s carcinoma recurred more than 17 years after initial diagnosis and 
treatment, despite adjuvant radiation therapy to the pelvis. This represents the longest 
time-to-recurrence reported in the literature after modern treatment with hysterectomy 
and adjuvant pelvic EBRT. Although rare, recurrences of endometrial carcinoma more 
than 10 years after initial treatment have been reported. There are 3 reports of 
endometrial carcinoma recurring more than 10 years after hysterectomy. However, none 
of these patients received adjuvant EBRT. The first report represents the lengthiest 
interval to recurrence, 318 months (26.5 years), in a patient originally treated in 1958, 
with preoperative uterine radium packing, followed by radical hysterectomy [7]. The 
second report of protracted time-to-recurrence was reported for an endometrial 
carcinoma recurrence in an abdominal scar 14 years after the initial surgery [8]. The third 
reported case is of a patient whose malignancy recurred in the upper urinary tract 11 
years after hysterectomy. Her relapse was successfully treated with surgical resection and 
EBRT [9]. 
Our patient was successfully treated with a salvage intracavitary HDR brachytherapy to 
the vaginal cuff; she remained disease free until her death 7 years later. HDR 
brachytherapy, independent of a history of primary adjuvant EBRT, has been shown to be 
an effective salvage option for those with isolated vaginal cuff recurrences [10]. The 
etiology of the recurrence may be posited to have been due to the senescence of tumor 
cells left behind after initial surgery, which survived through adjuvant radiation therapy. 
Another possibility to consider is the malignant transformation of endometriosis [11]. 
Our patient had no known history of endometriosis, and no evidence of ectopic uterine 
tissue was seen on the original pathology following hysterectomy; therefore, this scenario 
seems less likely. 
Later relapse predicts for a better median overall survival. A recent review reported 
that a disease-free interval of more than 12 months predicted a significantly longer 
median overall survival of 41 months, as compared to 13 months in those whose 
carcinoma recurred in less than 12 months [12]. Another review of patterns of relapse 
reported a difference between those who experienced recurrence after 24 months, with 
improved 5 and 10 year survival rates, as compared to those relapsing within 24 months 
[13]. 
In conclusion, very late recurrence may occur, even after treatment with adjuvant 
radiation therapy subsequent to hysterectomy for early stage endometrial carcinoma. 
With appropriate continued surveillance, it is possible to achieve early diagnosis and 
perform a successful salvage therapy. 
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Fig. 1. a Biopsy from the vaginal apex of the recurrence of endometrioid endometrial adenocarcinoma. 
H&E. b DAKO estrogen receptor at 1:100, using EDTA at pH 8 retrieval, with the DAKO LSAB+ 
detection system and the AEC chromogen on a DAKO Autostainer. 
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